Ernexa Therapeutics Inc. (ERNAW) Net income 2016–2025
Ernexa Therapeutics Inc. (ERNAW) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$14.1MFY2025 · since FY2016: -$2.9M → -$14.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$14.1M | +68.4% |
| FY2024 | -$44.5M | -105.6% |
| FY2023 | -$21.7M | +11.8% |
| FY2022 | -$24.6M | +79.9% |
| FY2021 | -$122.5M | -1580.8% |
| FY2020 | -$7.3M | -256.2% |
| FY2019 | -$2.0M | -690.3% |
| FY2018 | -$259,000 | +76.0% |
| FY2017 | -$1.1M | +63.2% |
| FY2016 | -$2.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Capital expendituresERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →